成纤维细胞生长因子 21 是一种参与 MASLD 进展的肝脏因子。

IF 5.8 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY United European Gastroenterology Journal Pub Date : 2024-10-01 Epub Date: 2024-06-18 DOI:10.1002/ueg2.12534
Rocío Gallego-Durán, Javier Ampuero, Douglas Maya-Miles, Helena Pastor-Ramírez, Rocío Montero-Vallejo, Jesús Rivera-Esteban, Leticia Álvarez-Amor, María Jesús Pareja, María Carmen Rico, Raquel Millán, María José Robles-Frías, Rocío Aller, Ángela Rojas, Rocío Muñoz-Hernández, Antonio Gil-Gómez, Sheila Gato, María García-Lozano, María Teresa Arias-Loste, Javier Abad, José Luis Calleja, Raúl J Andrade, Javier Crespo, Águeda González-Rodríguez, Carmelo García-Monzón, Fausto Andreola, Juan Manuel Pericás, Rajiv Jalan, Francisco Martín-Bermudo, Manuel Romero-Gómez
{"title":"成纤维细胞生长因子 21 是一种参与 MASLD 进展的肝脏因子。","authors":"Rocío Gallego-Durán, Javier Ampuero, Douglas Maya-Miles, Helena Pastor-Ramírez, Rocío Montero-Vallejo, Jesús Rivera-Esteban, Leticia Álvarez-Amor, María Jesús Pareja, María Carmen Rico, Raquel Millán, María José Robles-Frías, Rocío Aller, Ángela Rojas, Rocío Muñoz-Hernández, Antonio Gil-Gómez, Sheila Gato, María García-Lozano, María Teresa Arias-Loste, Javier Abad, José Luis Calleja, Raúl J Andrade, Javier Crespo, Águeda González-Rodríguez, Carmelo García-Monzón, Fausto Andreola, Juan Manuel Pericás, Rajiv Jalan, Francisco Martín-Bermudo, Manuel Romero-Gómez","doi":"10.1002/ueg2.12534","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>We aimed to assess the role of FGF21 in metabolic dysfunction-associated steatotic liver disease (MASLD) at a multi-scale level.</p><p><strong>Methods: </strong>We used human MASLD pathology samples for FGF21 gene expression analyses (qPCR and RNAseq), serum to measure circulating FGF21 levels and DNA for genotyping the FGF21 rs838133 variant in both estimation and validation cohorts. A hepatocyte-derived cell line was exposed to free fatty acids at different timepoints. Finally, C57BL/6J mice were fed a high-fat and choline-deficient diet (CDA-HFD) for 16 weeks to assess hepatic FGF21 protein expression and FGF21 levels by ELISA.</p><p><strong>Results: </strong>A significant upregulation in FGF21 mRNA expression was observed in the liver analysed by both qPCR (fold change 5.32 ± 5.25 vs. 0.59 ± 0.66; p = 0.017) and RNA-Seq (3.5 fold; FDR: 0.006; p < 0.0001) in MASLD patients vs. controls. Circulating levels of FGF21 were increased in patients with steatohepatitis vs. bland steatosis (386.6 ± 328.9 vs. 297.9 ± 231.5 pg/mL; p = 0.009). Besides, sex, age, A-allele from FGF21, GG genotype from PNPLA3, ALT, type 2 diabetes mellitus and BMI were independently associated with MASH and significant fibrosis in both estimation and validation cohorts. In vitro exposure of Huh7.5 cells to high concentrations of free fatty acids (FFAs) resulted in overexpression of FGF21 (p < 0.001). Finally, Circulating FGF21 levels and hepatic FGF21 expression were found to be significantly increased (p < 0.001) in animals under CDA-HFD.</p><p><strong>Conclusions: </strong>Hepatic and circulating FGF21 expression was increased in MASH patients, in Huh7.5 cells under FFAs and in CDA-HFD animals. The A-allele from the rs838133 variant was also associated with an increased risk of steatohepatitis and significant and advanced fibrosis in MASLD patients.</p>","PeriodicalId":23444,"journal":{"name":"United European Gastroenterology Journal","volume":" ","pages":"1056-1068"},"PeriodicalIF":5.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485537/pdf/","citationCount":"0","resultStr":"{\"title\":\"Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.\",\"authors\":\"Rocío Gallego-Durán, Javier Ampuero, Douglas Maya-Miles, Helena Pastor-Ramírez, Rocío Montero-Vallejo, Jesús Rivera-Esteban, Leticia Álvarez-Amor, María Jesús Pareja, María Carmen Rico, Raquel Millán, María José Robles-Frías, Rocío Aller, Ángela Rojas, Rocío Muñoz-Hernández, Antonio Gil-Gómez, Sheila Gato, María García-Lozano, María Teresa Arias-Loste, Javier Abad, José Luis Calleja, Raúl J Andrade, Javier Crespo, Águeda González-Rodríguez, Carmelo García-Monzón, Fausto Andreola, Juan Manuel Pericás, Rajiv Jalan, Francisco Martín-Bermudo, Manuel Romero-Gómez\",\"doi\":\"10.1002/ueg2.12534\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>We aimed to assess the role of FGF21 in metabolic dysfunction-associated steatotic liver disease (MASLD) at a multi-scale level.</p><p><strong>Methods: </strong>We used human MASLD pathology samples for FGF21 gene expression analyses (qPCR and RNAseq), serum to measure circulating FGF21 levels and DNA for genotyping the FGF21 rs838133 variant in both estimation and validation cohorts. A hepatocyte-derived cell line was exposed to free fatty acids at different timepoints. Finally, C57BL/6J mice were fed a high-fat and choline-deficient diet (CDA-HFD) for 16 weeks to assess hepatic FGF21 protein expression and FGF21 levels by ELISA.</p><p><strong>Results: </strong>A significant upregulation in FGF21 mRNA expression was observed in the liver analysed by both qPCR (fold change 5.32 ± 5.25 vs. 0.59 ± 0.66; p = 0.017) and RNA-Seq (3.5 fold; FDR: 0.006; p < 0.0001) in MASLD patients vs. controls. Circulating levels of FGF21 were increased in patients with steatohepatitis vs. bland steatosis (386.6 ± 328.9 vs. 297.9 ± 231.5 pg/mL; p = 0.009). Besides, sex, age, A-allele from FGF21, GG genotype from PNPLA3, ALT, type 2 diabetes mellitus and BMI were independently associated with MASH and significant fibrosis in both estimation and validation cohorts. In vitro exposure of Huh7.5 cells to high concentrations of free fatty acids (FFAs) resulted in overexpression of FGF21 (p < 0.001). Finally, Circulating FGF21 levels and hepatic FGF21 expression were found to be significantly increased (p < 0.001) in animals under CDA-HFD.</p><p><strong>Conclusions: </strong>Hepatic and circulating FGF21 expression was increased in MASH patients, in Huh7.5 cells under FFAs and in CDA-HFD animals. The A-allele from the rs838133 variant was also associated with an increased risk of steatohepatitis and significant and advanced fibrosis in MASLD patients.</p>\",\"PeriodicalId\":23444,\"journal\":{\"name\":\"United European Gastroenterology Journal\",\"volume\":\" \",\"pages\":\"1056-1068\"},\"PeriodicalIF\":5.8000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485537/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"United European Gastroenterology Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ueg2.12534\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"United European Gastroenterology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ueg2.12534","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:我们旨在从多尺度评估FGF21在代谢功能障碍相关性脂肪性肝病(MASLD)中的作用:我们使用人类 MASLD 病理样本进行 FGF21 基因表达分析(qPCR 和 RNAseq),使用血清测量循环中的 FGF21 水平,并使用 DNA 对估计队列和验证队列中的 FGF21 rs838133 变体进行基因分型。肝细胞衍生细胞系在不同时间点暴露于游离脂肪酸。最后,用高脂肪和胆碱缺乏饮食(CDA-HFD)喂养 C57BL/6J 小鼠 16 周,用 ELISA 评估肝脏 FGF21 蛋白表达和 FGF21 水平:通过 qPCR(折叠变化 5.32 ± 5.25 vs. 0.59 ± 0.66;p = 0.017)和 RNA-Seq(3.5 倍;FDR:0.006;p 结论:肝脏和循环中的 FGF21 mRNA 表达量明显增加:肝脏和循环中的 FGF21 表达在 MASH 患者、FFAs 下的 Huh7.5 细胞和 CDA-HFD 动物中均有所增加。rs838133变异体的A等位基因也与MASLD患者患脂肪性肝炎的风险增加以及严重和晚期肝纤维化有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.

Aim: We aimed to assess the role of FGF21 in metabolic dysfunction-associated steatotic liver disease (MASLD) at a multi-scale level.

Methods: We used human MASLD pathology samples for FGF21 gene expression analyses (qPCR and RNAseq), serum to measure circulating FGF21 levels and DNA for genotyping the FGF21 rs838133 variant in both estimation and validation cohorts. A hepatocyte-derived cell line was exposed to free fatty acids at different timepoints. Finally, C57BL/6J mice were fed a high-fat and choline-deficient diet (CDA-HFD) for 16 weeks to assess hepatic FGF21 protein expression and FGF21 levels by ELISA.

Results: A significant upregulation in FGF21 mRNA expression was observed in the liver analysed by both qPCR (fold change 5.32 ± 5.25 vs. 0.59 ± 0.66; p = 0.017) and RNA-Seq (3.5 fold; FDR: 0.006; p < 0.0001) in MASLD patients vs. controls. Circulating levels of FGF21 were increased in patients with steatohepatitis vs. bland steatosis (386.6 ± 328.9 vs. 297.9 ± 231.5 pg/mL; p = 0.009). Besides, sex, age, A-allele from FGF21, GG genotype from PNPLA3, ALT, type 2 diabetes mellitus and BMI were independently associated with MASH and significant fibrosis in both estimation and validation cohorts. In vitro exposure of Huh7.5 cells to high concentrations of free fatty acids (FFAs) resulted in overexpression of FGF21 (p < 0.001). Finally, Circulating FGF21 levels and hepatic FGF21 expression were found to be significantly increased (p < 0.001) in animals under CDA-HFD.

Conclusions: Hepatic and circulating FGF21 expression was increased in MASH patients, in Huh7.5 cells under FFAs and in CDA-HFD animals. The A-allele from the rs838133 variant was also associated with an increased risk of steatohepatitis and significant and advanced fibrosis in MASLD patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
United European Gastroenterology Journal
United European Gastroenterology Journal GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
10.50
自引率
13.30%
发文量
147
期刊介绍: United European Gastroenterology Journal (UEG Journal) is the official Journal of the United European Gastroenterology (UEG), a professional non-profit organisation combining all the leading European societies concerned with digestive disease. UEG’s member societies represent over 22,000 specialists working across medicine, surgery, paediatrics, GI oncology and endoscopy, which makes UEG a unique platform for collaboration and the exchange of knowledge.
期刊最新文献
Nodular Regenerative Hyperplasia: Report of 82 Patients and Systematic Review of Literature. Risk of Cancer Diagnosis in Patients With Eosinophilic Esophagitis Using a Nationwide Swedish Population Cohort. Expanding Support Beyond Clinical Care in IBD Patients. Prior metabolic and bariatric surgery is an independent determinant of severity of decompensation in alcohol-associated liver disease. Heterogeneity of definition of upper gastrointestinal tract in different guidelines of Crohn's disease: A scoping review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1